{"entity":{"id":"nct07523529","kind":"trial","name":"Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Fludarabine and Cyclophosphamide in advanced solid tumours, run by Beijing Biotech, now recruiting.","summary":"Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07523529 by Beijing Biotech, with 72 participants planned, started 2026-03-02 and due to reach its primary completion in 2027-04-14. Interventions recorded: Autologous dual-target CAR-T cells selected from the predefined target library., Fludarabine and Cyclophosphamide.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07523529","url":"https://clinicaltrials.gov/study/NCT07523529"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["fludarabine","cyclophosphamide"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07523529","phase":"1/2","setting":"A Phase 1/2, Open-Label, Biomarker-Guided Master Protocol Evaluating Autologous Dual-Target CAR-T Cells Selected From a Predefined Target Library in Adults With Advanced Solid Tumors","sponsor":"Beijing Biotech","enrolled":72,"outcomes":[]},"route":"/trials/nct07523529/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"},{"id":"fludarabine","kind":"drug","name":"Fludarabine","route":"/drugs/fludarabine/"}]}}